Overview

Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this 7- to 13-month study is to determine the efficacy of 8 mg/day oral perindopril to prevent the recurrence of atrial fibrillation (AF) in patients with essential hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Montreal Heart Institute
Collaborator:
Servier
Treatments:
Perindopril